Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156841 | 0.93 | GAA (0.59) | ROCK2ROCK1CCR2GAALTA4H | |
| SCHEMBL6154433 | 0.91 | LTA4H (0.61) | ROCK2ROCK1CCR2GAALTA4H | |
| SCHEMBL6153555 | 0.85 | LTA4H (0.66) | ROCK2ROCK1CCR2GAALTA4H | |
| SCHEMBL5870954 | 0.85 | ROCK2 (0.65) | ROCK2ROCK1CCR2GAAKAT2B | |
| SCHEMBL6399567 | 0.84 | KDM4E (0.59) | ROCK2ROCK1CCR2BCHE | |
| Hydrochloric Acid SCHEMBL6157025 | 0.84 | LTA4H (0.65) | ROCK2ROCK1CCR2GAALTA4H | |
| SCHEMBL6153938 | 0.84 | KAT2B (0.53) | ROCK2CCR2JAK2JAK3DRD2 | |
| SCHEMBL6154448 | 0.82 | ROCK2 (0.61) | ROCK2ROCK1CCR2GAALTA4H | |
| SCHEMBL6153741 | 0.80 | DRD4 (0.61) | ROCK2ROCK1CCR2JAK2JAK3 | |
| SCHEMBL27936853 | 0.80 | DRD2 (0.57) | CCR2JAK2JAK3LTA4HDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | ROCK2 2/4885ROCK1 1/4885CCR2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.